Knight Therapeutics Inc (OTCMKTS:KHTRF) shares traded up 0.9% during trading on Wednesday . The stock traded as high as $5.76 and last traded at $5.76, 100 shares traded hands during mid-day trading. A decline of 98% from the average session volume of 4,251 shares. The stock had previously closed at $5.71.

Separately, Paradigm Capital reaffirmed a “hold” rating on shares of Knight Therapeutics in a research report on Friday, April 5th.

The company’s 50-day moving average is $5.68.

About Knight Therapeutics (OTCMKTS:KHTRF)

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; and NERLYNX for the treatment of HER2-positive breast cancer.

Read More: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.